Zacks Investment Research Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to Buy

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The firm currently has a $113.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential downside of 0.13% from the stock’s current price.

According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “

A number of other equities analysts have also commented on ASND. BidaskClub raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. SVB Leerink reaffirmed an “outperform” rating and issued a $152.00 price target (up from $140.00) on shares of Ascendis Pharma A/S in a report on Tuesday, December 3rd. ValuEngine raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Wednesday, March 4th. Oppenheimer assumed coverage on Ascendis Pharma A/S in a report on Thursday, March 19th. They issued an “outperform” rating and a $199.00 price target for the company. Finally, Morgan Stanley raised their price target on Ascendis Pharma A/S from $148.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Ascendis Pharma A/S presently has an average rating of “Buy” and an average price target of $158.25.

Shares of Ascendis Pharma A/S stock traded up $2.20 during trading hours on Tuesday, reaching $113.15. The company had a trading volume of 275,300 shares, compared to its average volume of 183,232. Ascendis Pharma A/S has a one year low of $90.06 and a one year high of $145.59. The business has a fifty day simple moving average of $127.55 and a 200 day simple moving average of $119.15. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.74 and a quick ratio of 15.75. The firm has a market cap of $5.30 billion, a PE ratio of -26.45 and a beta of 0.82.

Institutional investors have recently bought and sold shares of the company. Nuveen Asset Management LLC raised its position in shares of Ascendis Pharma A/S by 27.0% in the fourth quarter. Nuveen Asset Management LLC now owns 16,536 shares of the biotechnology company’s stock worth $2,300,000 after buying an additional 3,516 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 32,647 shares of the biotechnology company’s stock worth $4,541,000 after buying an additional 132 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Ascendis Pharma A/S by 0.4% in the fourth quarter. Alliancebernstein L.P. now owns 537,086 shares of the biotechnology company’s stock worth $74,719,000 after buying an additional 1,940 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 284.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,253,004 shares of the biotechnology company’s stock worth $174,318,000 after buying an additional 926,762 shares in the last quarter. Finally, RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 1.3% in the fourth quarter. RA Capital Management L.P. now owns 4,185,342 shares of the biotechnology company’s stock worth $582,265,000 after buying an additional 52,900 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Bar Chart

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.